RxDoctor Payments Data

Alonso Alvarez, MD

Urology · Tampa, FLNPI 1952502650

Payments from drug & device makers

$4,347in general payments, 2019–2025

Across 167 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Axonics, Inc.$861
  • Astellas Pharma US Inc$547
  • Procept Biorobotics Corporation$285
  • Sumitomo Pharma America, Inc.$220
  • Pfizer$198
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$130%
  • Food & beverage$4,24598%
  • Education$882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,347 in reported general payments places this provider in the 50th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$71,834
Medicare patients
195
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron482$442,654
Lupron DepotLeuprolide Acetate38$225,984
EligardLeuprolide Acetate31$40,189
PremarinEstrogens, Conjugated39$17,234
Tadalafil108$14,096
Tolterodine Tartrate ErTolterodine Tartrate135$13,688
Tamsulosin Hcl1,125$10,358
Estradiol155$9,915
GemtesaVibegron11$9,589
Mirabegron ErMirabegron14$8,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,686
Finasteride642$7,519
Testosterone Cypionate133$3,930
Dutasteride74$2,880
Potassium Citrate ErPotassium Citrate43$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$547$442,654482 claims
AbbVieLupron Depot$165$225,98438 claims
PfizerPremarin$198$17,23439 claims
Sumitomo Pharma America, Inc.Gemtesa$220$9,58911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 urology providers in Florida.

Other urology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →